NO20013701D0 - HER-2/neu-fusjonsproteiner - Google Patents
HER-2/neu-fusjonsproteinerInfo
- Publication number
- NO20013701D0 NO20013701D0 NO20013701A NO20013701A NO20013701D0 NO 20013701 D0 NO20013701 D0 NO 20013701D0 NO 20013701 A NO20013701 A NO 20013701A NO 20013701 A NO20013701 A NO 20013701A NO 20013701 D0 NO20013701 D0 NO 20013701D0
- Authority
- NO
- Norway
- Prior art keywords
- fusion proteins
- neu
- neu fusion
- nucleic acid
- acid molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11797699P | 1999-01-29 | 1999-01-29 | |
| PCT/US2000/002164 WO2000044899A1 (en) | 1999-01-29 | 2000-01-28 | Her-2/neu fusion proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20013701D0 true NO20013701D0 (no) | 2001-07-27 |
| NO20013701L NO20013701L (no) | 2001-09-28 |
Family
ID=22375831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20013701A NO20013701L (no) | 1999-01-29 | 2001-07-27 | HER-2/neu-fusjonsproteiner |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1147190B1 (no) |
| JP (1) | JP5164300B2 (no) |
| KR (1) | KR100766653B1 (no) |
| CN (1) | CN1201004C (no) |
| AT (1) | ATE474048T1 (no) |
| AU (1) | AU780109B2 (no) |
| BR (1) | BR0007840A (no) |
| CA (1) | CA2361009C (no) |
| CZ (1) | CZ20012587A3 (no) |
| DE (1) | DE60044665D1 (no) |
| ES (1) | ES2348708T3 (no) |
| HU (1) | HUP0105303A2 (no) |
| IL (1) | IL144371A0 (no) |
| MX (1) | MXPA01007721A (no) |
| NO (1) | NO20013701L (no) |
| NZ (1) | NZ513062A (no) |
| TR (1) | TR200102191T2 (no) |
| WO (1) | WO2000044899A1 (no) |
| ZA (1) | ZA200106179B (no) |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7198920B1 (en) | 1999-01-29 | 2007-04-03 | Corika Corporation | HER-2/neu fusion proteins |
| US6984384B1 (en) | 1999-09-30 | 2006-01-10 | Health Research, Inc. | Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
| US7378096B2 (en) | 1999-09-30 | 2008-05-27 | Health Research, Inc. | Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
| AU2744201A (en) * | 1999-12-29 | 2001-07-09 | Corixa Corporation | Murine neu sequences and methods of use therefor |
| DE60144516D1 (de) * | 2000-03-30 | 2011-06-09 | Dendreon Corp | Zusammensetzungen und verfahren für eine auf dendritischen zellen basierende immuntherapie |
| US7229623B1 (en) | 2000-08-03 | 2007-06-12 | Corixa Corporation | Her-2/neu fusion proteins |
| KR20030048009A (ko) * | 2000-08-14 | 2003-06-18 | 코릭사 코포레이션 | Ｈｅｒ-2/ｎｅｕ 관련 악성 종양의 치료 및 진단용 조성물및 방법 |
| JP2004511527A (ja) * | 2000-10-18 | 2004-04-15 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
| SI2266603T1 (sl) | 2000-10-18 | 2012-12-31 | Glaxosmithkline Biologicals S.A. | Tumorska cepiva |
| GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
| AU2002354644C1 (en) | 2001-07-10 | 2009-04-30 | Corixa Corporation | Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres |
| AU2004207233C1 (en) | 2003-01-24 | 2008-04-24 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled 254P1D6B useful in treatment and detection of cancer |
| AU2004289170B2 (en) * | 2003-06-06 | 2009-12-17 | Agennix Incorporated | Lactoferrin as an adjuvant in cancer vaccines |
| ATE429447T1 (de) * | 2003-06-25 | 2009-05-15 | Bn Immunotherapeutics Inc | Aufreinigung von her-2-varianten |
| US7763452B2 (en) | 2003-06-25 | 2010-07-27 | Bn Immunotherapeutics, Inc. | Purification of HER-2 variants |
| JP4772674B2 (ja) * | 2003-07-21 | 2011-09-14 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ヒト上皮成長因子２／ｎｅｕ抗原をコードする合成遺伝子およびその用途 |
| GB0321615D0 (en) | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
| NZ583292A (en) | 2003-11-06 | 2012-03-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
| MXPA06014065A (es) | 2004-06-01 | 2007-01-31 | Genentech Inc | Conjugados de droga-anticuerpo y metodos. |
| ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| ITMI20041965A1 (it) * | 2004-10-15 | 2005-01-15 | Augusto Amici | "dna codificante forme tronche e chimeriche della proteina p185neu e suoi usi terapeutici" |
| GB0427131D0 (en) * | 2004-12-10 | 2005-01-12 | Glaxosmithkline Biolog Sa | Novel combination |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| US20100021424A1 (en) | 2006-06-02 | 2010-01-28 | Vincent Brichard | Method For Identifying Whether A Patient Will Be Responder or Not to Immunotherapy |
| US20090035360A1 (en) | 2007-05-24 | 2009-02-05 | Dominique Ingrid Lemoine | Lyophilised antigen composition |
| CA2809819A1 (en) | 2009-09-09 | 2011-03-17 | Centrose, Llc | Extracellular targeted drug conjugates |
| GB0917457D0 (en) | 2009-10-06 | 2009-11-18 | Glaxosmithkline Biolog Sa | Method |
| US20110256157A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
| JP2013534520A (ja) | 2010-06-08 | 2013-09-05 | ジェネンテック， インコーポレイテッド | システイン操作抗体及びコンジュゲート |
| ES2544608T3 (es) | 2010-11-17 | 2015-09-02 | Genentech, Inc. | Conjugados de anticuerpo y de alaninil-maitansinol |
| CA2833212C (en) | 2011-05-12 | 2020-06-09 | Genentech, Inc. | Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides |
| HRP20151374T1 (hr) | 2011-10-14 | 2016-01-15 | Medimmune Limited | Pirolobenzodiazepini i njihovi konjugati |
| WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
| EP2906250B1 (en) | 2012-10-12 | 2018-05-30 | ADC Therapeutics SA | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
| JP6270859B2 (ja) | 2012-10-12 | 2018-01-31 | エイディーシー・セラピューティクス・エス・アー・エール・エルＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａｒｌ | ピロロベンゾジアゼピン−抗体結合体 |
| JP6392764B2 (ja) | 2012-10-12 | 2018-09-19 | エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ | ピロロベンゾジアゼピン−抗体結合体 |
| HUE045435T2 (hu) | 2012-10-12 | 2019-12-30 | Medimmune Ltd | Pirrolobenzodiazepinek és konjugátumaik |
| EP2906297B1 (en) | 2012-10-12 | 2017-12-06 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
| HRP20182129T1 (hr) | 2012-10-12 | 2019-02-08 | Adc Therapeutics Sa | Konjugati protutijelo - pirolobenzodiazepin |
| LT2906251T (lt) | 2012-10-12 | 2017-12-11 | Adc Therapeutics Sa | Pirolobenzodiazepino-anti-cd22 antikūno konjugatai |
| US9567340B2 (en) | 2012-12-21 | 2017-02-14 | Medimmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
| AU2013366493B2 (en) | 2012-12-21 | 2017-08-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| CA2904044C (en) | 2013-03-13 | 2020-03-31 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| JP6444902B2 (ja) | 2013-03-13 | 2018-12-26 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン及びその結合体 |
| CN105307685B (zh) | 2013-03-13 | 2019-03-08 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓和其结合物 |
| MX2016001862A (es) | 2013-08-12 | 2016-08-03 | Genentech Inc | Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo[e]indol, y metodos de uso y tratamiento. |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| US9950078B2 (en) | 2013-10-11 | 2018-04-24 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| WO2015052532A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| US9956299B2 (en) | 2013-10-11 | 2018-05-01 | Medimmune Limited | Pyrrolobenzodiazepine—antibody conjugates |
| JP6425327B2 (ja) * | 2013-12-12 | 2018-11-21 | 国立大学法人東京農工大学 | タンパク質−磁性粒子複合体及びその製造方法 |
| EP3082874A2 (en) | 2013-12-16 | 2016-10-26 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
| AU2014364927A1 (en) | 2013-12-16 | 2016-07-07 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
| JP6980384B2 (ja) | 2013-12-16 | 2021-12-15 | ジェネンテック， インコーポレイテッド | １−（クロロメチル）−２，３−ジヒドロ−１ｈ−ベンゾ［ｅ］インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法 |
| JP6531166B2 (ja) | 2014-09-10 | 2019-06-12 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン及びそのコンジュゲート |
| JP6622293B2 (ja) | 2014-09-12 | 2019-12-18 | ジェネンテック， インコーポレイテッド | アントラサイクリンジスルフィド中間体、抗体−薬物複合体、及び方法 |
| AU2015314826A1 (en) | 2014-09-12 | 2017-03-02 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| CA2959689A1 (en) | 2014-09-17 | 2016-03-24 | Genentech, Inc. | Pyrrolobenzodiazepines and antibody disulfide conjugates thereof |
| EP3223854A1 (en) | 2014-11-25 | 2017-10-04 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
| KR20170086121A (ko) | 2014-12-03 | 2017-07-25 | 제넨테크, 인크. | 4급 아민 화합물 및 그의 항체-약물 접합체 |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
| MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
| MA45326A (fr) | 2015-10-20 | 2018-08-29 | Genentech Inc | Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| EP3433621A1 (en) | 2016-03-25 | 2019-01-30 | H. Hoffnabb-La Roche Ag | Multiplexed total antibody and antibody-conjugated drug quantification assay |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| PL3458101T3 (pl) | 2016-05-20 | 2021-05-31 | F. Hoffmann-La Roche Ag | Koniugaty PROTAC-przeciwciało i sposoby ich stosowania |
| WO2017205741A1 (en) | 2016-05-27 | 2017-11-30 | Genentech, Inc. | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
| CN109476648B (zh) | 2016-06-06 | 2022-09-13 | 豪夫迈·罗氏有限公司 | 司维司群抗体-药物缀合物和使用方法 |
| EP3496763A1 (en) | 2016-08-11 | 2019-06-19 | Genentech, Inc. | Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof |
| EP3522933B1 (en) | 2016-10-05 | 2021-12-15 | F. Hoffmann-La Roche AG | Methods for preparing antibody drug conjugates |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| KR20200032243A (ko) | 2017-02-08 | 2020-03-25 | 에이디씨 테라퓨틱스 에스에이 | 피롤로벤조디아제핀-항체 컨주게이트 |
| SI3612537T1 (sl) | 2017-04-18 | 2022-10-28 | Medimmune Limited | Konjugati pirolobenzodiazepina |
| EP3612234B1 (en) | 2017-04-20 | 2024-03-13 | ADC Therapeutics SA | Combination therapy with an anti-axl antibody-drug conjugate |
| KR102442736B1 (ko) | 2017-06-14 | 2022-09-16 | 에이디씨 테라퓨틱스 에스에이 | 항-cd19 adc의 투여를 위한 투약량 체제 |
| CN111065638B (zh) | 2017-08-18 | 2021-04-09 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂䓬缀合物 |
| CN111788208B (zh) | 2017-09-20 | 2023-11-24 | Ph制药有限公司 | 泰兰他汀类似物 |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
| AU2019365238A1 (en) | 2018-10-24 | 2021-05-13 | F. Hoffmann-La Roche Ag | Conjugated chemical inducers of degradation and methods of use |
| WO2020123275A1 (en) | 2018-12-10 | 2020-06-18 | Genentech, Inc. | Photocrosslinking peptides for site specific conjugation to fc-containing proteins |
| GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
| IL286326B2 (en) | 2019-03-15 | 2025-10-01 | Medimmune Ltd | Azatidobenzodiazepine dimers and conjugates containing them for use in the treatment of cancer |
| WO2022013189A1 (en) * | 2020-07-14 | 2022-01-20 | F. Hoffmann-La Roche Ag | Assays for fixed dose combinations |
| GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
| CA3236930A1 (en) | 2021-11-03 | 2022-04-21 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
| TW202432187A (zh) | 2022-12-23 | 2024-08-16 | 美商建南德克公司 | 小腦蛋白降解劑結合物及其用途 |
| KR102584276B1 (ko) * | 2023-03-30 | 2023-10-10 | 주식회사 애스톤사이언스 | Her2 백신, 및 면역관문 억제제의 조합 요법 |
| AU2024257248A1 (en) | 2023-04-17 | 2025-11-06 | Peak Bio, Inc. | Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0474727T3 (da) * | 1989-05-19 | 1998-01-12 | Genentech Inc | HER2 ekstracellulært domæne |
| US5801005A (en) * | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| JPH0914357A (ja) * | 1995-06-27 | 1997-01-14 | Honda Motor Co Ltd | 伝動ベルト用ブロック |
-
2000
- 2000-01-28 CN CNB008057524A patent/CN1201004C/zh not_active Expired - Fee Related
- 2000-01-28 IL IL14437100A patent/IL144371A0/xx unknown
- 2000-01-28 NZ NZ513062A patent/NZ513062A/en unknown
- 2000-01-28 CA CA2361009A patent/CA2361009C/en not_active Expired - Fee Related
- 2000-01-28 MX MXPA01007721A patent/MXPA01007721A/es not_active Application Discontinuation
- 2000-01-28 BR BR0007840-9A patent/BR0007840A/pt not_active IP Right Cessation
- 2000-01-28 AU AU27426/00A patent/AU780109B2/en not_active Ceased
- 2000-01-28 HU HU0105303A patent/HUP0105303A2/hu unknown
- 2000-01-28 ES ES00905800T patent/ES2348708T3/es not_active Expired - Lifetime
- 2000-01-28 AT AT00905800T patent/ATE474048T1/de not_active IP Right Cessation
- 2000-01-28 DE DE60044665T patent/DE60044665D1/de not_active Expired - Lifetime
- 2000-01-28 WO PCT/US2000/002164 patent/WO2000044899A1/en not_active Ceased
- 2000-01-28 EP EP00905800A patent/EP1147190B1/en not_active Expired - Lifetime
- 2000-01-28 KR KR1020017009563A patent/KR100766653B1/ko not_active Expired - Fee Related
- 2000-01-28 CZ CZ20012587A patent/CZ20012587A3/cs unknown
- 2000-01-28 JP JP2000596141A patent/JP5164300B2/ja not_active Expired - Fee Related
- 2000-01-28 TR TR2001/02191T patent/TR200102191T2/xx unknown
-
2001
- 2001-07-26 ZA ZA200106179A patent/ZA200106179B/en unknown
- 2001-07-27 NO NO20013701A patent/NO20013701L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1044798A1 (en) | 2002-11-01 |
| CZ20012587A3 (cs) | 2002-05-15 |
| HUP0105303A2 (en) | 2002-05-29 |
| NO20013701L (no) | 2001-09-28 |
| KR100766653B1 (ko) | 2007-10-15 |
| ES2348708T3 (es) | 2010-12-13 |
| ATE474048T1 (de) | 2010-07-15 |
| TR200102191T2 (tr) | 2001-12-21 |
| WO2000044899A1 (en) | 2000-08-03 |
| ZA200106179B (en) | 2002-12-24 |
| CA2361009C (en) | 2012-10-23 |
| JP5164300B2 (ja) | 2013-03-21 |
| NZ513062A (en) | 2003-10-31 |
| AU2742600A (en) | 2000-08-18 |
| JP2002535004A (ja) | 2002-10-22 |
| DE60044665D1 (de) | 2010-08-26 |
| IL144371A0 (en) | 2002-05-23 |
| CN1345374A (zh) | 2002-04-17 |
| BR0007840A (pt) | 2002-01-22 |
| EP1147190B1 (en) | 2010-07-14 |
| CA2361009A1 (en) | 2000-08-03 |
| CN1201004C (zh) | 2005-05-11 |
| KR20010101865A (ko) | 2001-11-15 |
| MXPA01007721A (es) | 2003-07-14 |
| EP1147190A1 (en) | 2001-10-24 |
| AU780109B2 (en) | 2005-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20013701D0 (no) | HER-2/neu-fusjonsproteiner | |
| WO2002012341A3 (en) | Her-2/neu fusion proteins | |
| HUP0302532A2 (hu) | Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások | |
| FI932678A0 (fi) | Pao alfavirus baserande DNA expressionssystem | |
| BR0113921A (pt) | ácidos nucléicos e polipeptìdeos receptores | |
| DE69634912D1 (de) | Intrazellulare domäne des her-2/neu proteins, für die prevention oder behandlung von bösartigen tumoren | |
| SG153874A1 (en) | Neutralizing epitope-based growth enhancing vaccine | |
| HUP0002095A2 (hu) | Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk | |
| BRPI0511118A (pt) | polipeptìdeos de haemophilus influenzae não transcritos | |
| CY1114265T1 (el) | Πρωτεϊνη συντηξης αλβουμινης | |
| BR9608615A (pt) | Vacinas de vírus sincicial respiratório de ácido nucléico | |
| CY1107351T1 (el) | Καινοφανης μεταλλαγμενη μορφη απιμινασης αργινινης | |
| DE19580890D2 (de) | Lebendvakzine zur Behandlung von Tumorerkrankungen | |
| PT97103A (pt) | Moleculas de acido nucleico isoladas e vacinas contra gp75 que as contem | |
| DK1082423T3 (da) | Cyclin E2-gener og -proteiner | |
| DK1290160T3 (da) | Humane Pellino-polypeptider | |
| WO2001040313A3 (en) | Feline immunoregulatory proteins, nucleic acid molecules, and uses thereof | |
| AU6987696A (en) | The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells | |
| ATE381351T1 (de) | Anwendung des herpes simplex virus glykoproteins- d zur unterdrückung von immunantworten | |
| WO2001004143A3 (en) | Prostase vaccine | |
| BR0207033A (pt) | variantes de amina oxidase ap1 | |
| WO2003016343A3 (en) | USE OF αCP1, αCP2, AND HUR FOR MODULATING GENE EXPRESSION AND INDUCING ANGIOGENESIS | |
| BR0110791A (pt) | Composição, métodos para induzir uma resposta imune em um indivìduo contra um imunogene, para modular o sistema imune de um indivìduo e para imunizar um indivìduo contra um patógeno, vacina recombinante, e patógeno atenuado vivo | |
| NO20005321L (no) | Vertskodet protein uttrykt i Mareks sykdoms (MDV) infiserte celler og antistoffer til dette | |
| DK1077720T3 (da) | Præparat til induktion af en tumorspecifik immunrespons, fremgangsmåde til fremstilling heraf samt anvendelse af præparatet til behandling af neoplasier |